Down syndrome (DS) patients demonstrate the neuropathology of Alzheimer's disease (AD) characterized by the formation of senile plaques and neuroˆbrillary tangles by age 40 50 years. It has been considered for a number of years that 1.5-fold expression of the gene for the amyloid precursor protein (APP) located on chromosome 21 leading to overproduction of amyloid-b peptide (Ab) results in the early onset of AD in adults with DS. However, the mean age of onset of familial AD with the Swedish mutation on APP which has high a‹nity for b-secretase associated with a dramatic increase in Ab production is about 55 years. This paradox indicates that there is a poor correlation between average ages of AD onset and the theoretical amount of Ab production and that there are factors exacerbating AD on chromosome 21. We therefore focused on dual-speciˆcity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), since overexpressing transgenic mice show AD-like brain pathology. The overexpression of DYRK1A caused suppression of the activity of neprilysin (NEP), which is a major Ab-degrading enzyme in the brain, and phosphorylation at the NEP cytoplasmic domain. NEP activity was markedly reduced inˆbroblasts derived from DS patients compared with that in broblasts derived from healthy controls. This impaired activity of NEP was rescued by DYRK1A inhibition. These results show that DYRK1A overexpression causes suppression of NEP activity through its phosphorylation in DS patients. Our results suggest that DYRK1A inhibitors could be eŠective against AD not only in adults with DS but also in sporadic AD patients. 

